You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 49 No. 10, October 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLE
 This Article
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

The treatment of neurosarcoidosis with cyclosporine

B. J. Stern, S. A. Schonfeld, C. Sewell, A. Krumholz, P. Scott and G. Belendiuk
Department of Medicine, Sinai Hospital of Baltimore, MD 21215.

Six patients with refractory neurosarcoidosis were enrolled in a 12-month open-label trial to investigate the safety and efficacy of cyclosporine therapy. Patients were stabilized on a corticosteroid dose, randomized to a low-dose or high-dose cyclosporine group (with appropriate target whole blood cyclosporine levels) for 6 months, and assessed by prospectively defined studies. The corticosteroid dose was adjusted as clinically tolerated. We found that the corticosteroid dose could be lowered to 30% to 58% of the initial stabilization dose in conjunction with cyclosporine therapy, at the time of maximal clinical and laboratory improvement. However, four patients deteriorated while using corticosteroids and cyclosporine; one of these patients died. At the time of clinical deterioration, the prednisone dose ranged from 6 to 22.5 mg daily (or the equivalent). No serious toxic effects developed from cyclosporine therapy. Cyclosporine treatment is a reasonably safe and effective adjunct to corticosteroid therapy for patients with refractory neurosarcoidosis, although clinical deterioration can occur despite combination therapy.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interstitial lung disease guideline
Wells et al.
Thorax 2008;63:v1-v58.
FULL TEXT  

Sarcoidosis of the nervous system
Joseph and Scolding
PN 2007;7:234-244.
ABSTRACT | FULL TEXT  

Treatment of Corticosteroid-Resistant Neurosarcoidosis With a Short-Course Cyclophosphamide Regimen
Doty et al.
Chest 2003;124:2023-2026.
ABSTRACT | FULL TEXT  

Endocrine and reproductive manifestations of sarcoidosis
Porter et al.
QJM 2003;96:553-561.
FULL TEXT  

Statement on Sarcoidosis
Hunninghake
Am. J. Respir. Crit. Care Med. 1999;160:736-755.
FULL TEXT  

Central nervous system sarcoidosis—diagnosis and management
Zajicek et al.
QJM 1999;92:103-117.
ABSTRACT | FULL TEXT  

Effectiveness of Chloroquine and Hydroxychloroquine in Treating Selected Patients With Sarcoidosis With Neurological Involvement
Sharma
Arch Neurol 1998;55:1248-1254.
ABSTRACT | FULL TEXT  

Neurosarcoidosis as a Cause of Refractory Psychosis: A Complicated Case Report
Bona et al.
Am. J. Psychiatry 1998;155:1106-1108.
FULL TEXT  

Sarcoidosis
Newman et al.
NEJM 1997;336:1224-1234.
FULL TEXT  

Case 37-1996- A 51-Year-Old Man with Visual Problems and an Intracranial Mass
Gittinger and Hedley-Whyte
NEJM 1996;335:1668-1674.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.